SCHEMBL21564465

SCHEMBL21564465

CCOC(=O)/C=C/c1cn(COCC[Si](C)(C)C)c(=O)c(N2CCOCC2)n1

nearest known ligand 0.42

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.35
KDM4E B2RXH2 2/20 0.35
RXFP1 Q9HBX9 1/20 0.35
HPGD P15428 1/20 0.35
HSD17B10 Q99714 1/20 0.35
AKT1 P31749 2/20 0.35
DGAT1 O75907 2/20 0.34
HDAC6 Q9UBN7 2/20 0.34
PIK3CA P42336 2/20 0.34
L3MBTL1 Q9Y468 2/20 0.34
ALOX15 P16050 1/20 0.34
MTOR P42345 1/20 0.34
KLKB1 P03952 1/20 0.33
RAF1 P04049 1/20 0.33
BRAF P15056 1/20 0.33
MEN1 O00255 1/20 0.33
KMT2A Q03164 1/20 0.33
HTT P42858 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23257963 0.91 RXFP1 (0.35) ALDH1A1RXFP1DGAT1KLKB1KMT2A
SCHEMBL23258154 0.89 DGAT1 (0.33) DGAT1KLKB1
SCHEMBL26031543 0.86 PFKFB3 (0.36) KDM4EDGAT1KLKB1
SCHEMBL21564466 0.79 AKT1 (0.40) ALDH1A1RXFP1AKT1DGAT1PIK3CA
SCHEMBL21552828 0.79 KLKB1 (0.35) ALDH1A1KDM4ERXFP1DGAT1HDAC6
SCHEMBL21553173 0.77 KLKB1 (0.34) KLKB1
SCHEMBL21564586 0.77 DUT (0.34) PIK3CA
SCHEMBL21552930 0.76 PIK3CA (0.39) ALDH1A1DGAT1HDAC6PIK3CAL3MBTL1
SCHEMBL23258619 0.75 MAPT (0.43) ALDH1A1KDM4EHPGDHSD17B10AKT1
SCHEMBL21552857 0.75 KLKB1 (0.34) KLKB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230250090-A1 KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE IMAGO BIOSCIENCES INC (US) 2023-08-10 US disclosed
US-11578059-B2 KDM1A inhibitors for the treatment of disease Imago Biosciences. Inc. (US) 2023-02-14 US disclosed
US-20210115023-A1 KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE IMAGO BIOSCIENCES, INC. 2021-04-22 US disclosed
WO-2019217972-A1 KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE IMAGO BIOSCIENCES, INC. (US) 2019-11-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230250090-A1 KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE KDM1B, KDM1A, KDM2A ALDH1A1 839/4885KDM4E 18/4885RXFP1 4016/4885
US-20210115023-A1 KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE KDM1A, KDM1B, KDM2A ALDH1A1 599/4885KDM4E 18/4885RXFP1 3542/4885
US-11578059-B2 KDM1A inhibitors for the treatment of disease KDM1B, KDM1A, KDM2A ALDH1A1 839/4885KDM4E 18/4885RXFP1 4016/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.